Loading people...
Allan May is the Co-Founder and Chairman Emeritus of Life Science Angels, based in the San Francisco Bay Area. Since its inception in 2005, his investment group has deployed over $35 million across 32 early-stage medical device and biotechnology startups, subsequently attracting more than $700 million in follow-on venture capital. In 2007, he partnered with Dr. Thomas Fogarty to co-found Emergent Medical Partners, a boutique venture capital fund focused on early-stage medical device investments. Prior to his transition into full-time venture and angel investing, he served as the chief executive officer and founder for multiple healthcare startups, including Emerald Logic and Vascular Extension. May leverages his extensive operating experience to syndicate investments across various United States angel groups, maintaining a primary focus on funding and advancing early-stage life sciences and digital health enterprises.
Allan May stands out as a highly respected investor and a key figure within Life Science Angels, an organization renowned for its strategic investments in the burgeoning life sciences industry. As an active investor, Allan brings a wealth of experience and a keen eye for disruptive technologies to the group, contributing significantly to its mission of supporting groundbreaking scientific and medical advancements.
At Life Science Angels, Allan May's role involves rigorous due diligence, mentorship, and capital deployment into early-stage companies that demonstrate high potential for transforming healthcare. His investment focus areas are broad yet specialized, encompassing cutting-edge biotechnology, innovative medical devices, diagnostics, and emerging digital health solutions. He is particularly interested in ventures that address significant unmet medical needs, offer proprietary technology, and possess strong management teams capable of executing ambitious visions.
Allan's career background is rooted deeply in the life sciences, having accumulated years of experience that span various facets of the industry, including executive leadership, strategic development, and venture capital. This extensive operational and investment experience provides him with a unique perspective, enabling him to thoroughly evaluate complex scientific propositions and market opportunities. His expertise allows him to not only assess financial viability but also understand the scientific rigor and regulatory pathways critical for success in the life sciences sector. Prior to his involvement with Life Science Angels, Allan held influential positions where he was instrumental in guiding companies through critical growth phases, from product development to market entry.
While specific individual notable investments are often confidential in the angel investing world, Allan May has been a crucial contributor to Life Science Angels' portfolio, which includes numerous companies that have gone on to achieve significant milestones, secure further funding rounds, or successfully exit. His strategic insights have helped portfolio companies navigate challenges, refine their business models, and accelerate their path to commercialization. Allan's commitment extends beyond capital, often serving as a trusted advisor, connecting founders with essential resources and networks. His dedication to fostering innovation makes him an invaluable asset to both Life Science Angels and the broader life science entrepreneurial ecosystem.
Allan May is a prominent investor with Life Science Angels, an organization focused on funding early-stage companies in the life sciences sector. He specializes in identifying and supporting innovative ventures in biotechnology, medical devices, and digital health.
Allan May primarily invests in early-stage life science companies. His focus areas include biotechnology, medical devices, diagnostics, and digital health solutions that aim to address significant unmet medical needs and possess strong potential for growth.
Allan May works as an investor at Life Science Angels, a leading angel investment group dedicated to supporting and funding promising companies within the life sciences industry.
